Metrics as of 10/13/2026, 06:38 PM (Berlin time), refresh in progress.
Nasus Pharma Stock
Nasus Pharma Ltd.
Company data
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Country
- Israel
- CEO
- Brendan O'Grady
- Employees
- 7
- Market cap
- $27 M
- IPO
- 13/08/2025
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal…
Nasus Pharma stock: price history
1D
-5.1%
1W
-18.0%
1M
-7.4%
6M
+40.0%
YTD
-65.6%
1Y
-59.4%
2Y
–
5Y
–
10Y
–
Pattern chart
Pattern detected by the Market Jury detector vsqueeze-release-v1.0 on 13/10/26. Not a buy or sell signal.Beta
What does this mean?
Volatility squeeze
BearishPrice swings had compressed unusually tight beforehand (volatility near a low) and are now releasing into a stronger move. Technical analysis views such tight phases as often preceding a bigger move.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Nasus Pharma
Analyst assessment of Nasus Pharma
PRICE TARGET LOW
US$22.00
CONSENSUS
US$22.00
MEDIAN
US$22.00
PRICE TARGET HIGH
US$22.00
0
STRONG BUY
1
BUY
0
HOLD
0
SELL
0
STRONG SELL
1
TOTAL · Buy
As of: 26/03/2026
Nasus Pharma stock metrics
P/E
-3.03
P/B
3.17
EV/EBITDA
-2.7
RETURN ON EQUITY
-54.0%
NET MARGIN
0.0%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
33.1%
FLOAT SHARES
2,850,070
AVG. DAILY VOLUME (30D)
18,880
Insider transactions (SEC)
Teleman Dan Benjamin
Comparable stocks
Frequently asked questions about Nasus Pharma stock
What does Nasus Pharma do?
Nasus Pharma Ltd. is a company in the Healthcare sector, Medical - Pharmaceuticals industry, headquartered in Israel.
The CEO is Brendan O'Grady, the company employs around 7 people.
The IPO was on 13/08/2025; the stock trades on AMEX under the ticker NSRX.
What do analysts say about Nasus Pharma stock?
1 analysts rate the stock, the consensus is Buy (as of 26/03/2026).
The average price target is US$22.00, ranging from US$22.00 to US$22.00, with a median of US$22.00.
This is an external assessment, not a statement by Market Jury.
Does Nasus Pharma pay a dividend?
No, Nasus Pharma currently does not pay a dividend.
Which stocks are comparable to Nasus Pharma?
Comparable stocks include Corcept Therapeutics, Liquidia, Latigo Biotherapeutics, Helus Pharma, Teva Pharmaceutical Industries, Alpha Tau Medical, Eli Lilly and Company and Johnson & Johnson.
How can I get Nasus Pharma stock analyzed?
Clicking "Analyze stock" lets five strategies assess Nasus Pharma against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.